Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

3.30
-0.0400-1.20%
Post-market: 3.300.00000.00%18:48 EST
Volume:2.74M
Turnover:9.12M
Market Cap:788.91M
PE:-6.16
High:3.39
Open:3.36
Low:3.28
Close:3.34
52wk High:4.18
52wk Low:0.6925
Shares:239.06M
Float Shares:237.00M
Volume Ratio:0.98
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5358
EPS(LYR):-0.2764
ROE:97.76%
ROA:-5.42%
PB:-1.75
PE(LYR):-11.94

Loading ...

Esperion Therapeutics Announces Proposed Public Offering of Common Stock

Reuters
·
Oct 08, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Occidental Petroleum , GameStop, Alphabet

Reuters
·
Oct 03, 2025

Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040

Dow Jones
·
Oct 03, 2025

BRIEF-Esperion Reaches Settlement Agreement With ANDA Filer

Reuters
·
Oct 03, 2025

Esperion Therapeutics Reaches Settlement With Dr. Reddy’s, Delaying U.S. Generics of NEXLETOL and NEXLIZET Until 2040

Reuters
·
Oct 03, 2025

Esperion Therapeutics - DR. Reddy's Agrees Not to Market Generic Nexletol or Nexlizet Before 2040

THOMSON REUTERS
·
Oct 03, 2025

Esperion Reaches Settlement Agreement With Anda Filer, DR. Reddy’s Laboratories, Not to Market Generic Versions of Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) Prior to April 19, 2040

THOMSON REUTERS
·
Oct 03, 2025

Esperion Therapeutics - Patent Litigation Against Alkem, Aurobindo Pharma, Msn, Renata, Sandoz Is Ongoing

THOMSON REUTERS
·
Oct 03, 2025

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

GlobeNewswire
·
Oct 03, 2025

Esperion price target raised to $9 from $7 at Cantor Fitzgerald

TIPRANKS
·
Sep 26, 2025

Citizens JMP Sticks to Its Buy Rating for Esperion (ESPR)

TIPRANKS
·
Sep 25, 2025

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 19, 2025

Esperion Partner Otsuka Receives Approval for Nexletol in Japan

MT Newswires Live
·
Sep 19, 2025

Esperion Therapeutics Inc - Eligible for Sales Milestones and Royalties in Japan

THOMSON REUTERS
·
Sep 19, 2025

Esperion Partner Otsuka Receives Regulatory Approval to Market Nexletol® in Japan for the Treatment of Hypercholesterolemia

THOMSON REUTERS
·
Sep 19, 2025

BRIEF-Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Reuters
·
Aug 29, 2025

Esperion Therapeutics Inc - Bempedoic Acid Recommended for Patients Unable to Take Statin Therapy to Achieve Ldl-C Goal. Class I, Level B

THOMSON REUTERS
·
Aug 29, 2025